查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2097020

進行性遺傳性肝內膽汁淤積症治療市場－2026-2032年全球市場預測

Progressive Familial Intrahepatic Cholestasis Treatment Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，治療進行進行性遺傳性肝內膽汁淤積症的市場規模將成長至 1.7281 億美元，複合年成長率為 4.80%。

主要市場統計數據
基準年 2025 1.244億美元
預計年份：2026年 1.2987億美元
預測年份 2032 1.7281億美元
複合年成長率 (%) 4.80%

隨著罕見兒童肝病治療從症狀管理發展到精準診斷、標靶膽汁酸調節、基因分析和避免肝臟移植策略，進行性遺傳性肝內膽汁淤積症（PFIC）的治療也不斷進步。進行性遺傳性肝內膽汁淤積症（簡稱PFIC）是一組遺傳性膽汁淤積性疾病，由肝細胞膽汁生成和轉運缺陷所引起。其臨床特徵包括持續性膽汁淤積、嚴重搔癢、黃疸、生長遲緩、脂溶性維生素缺乏、門靜脈高壓、進展至肝功能衰竭。診斷越來越依賴生化評估、肝臟影像檢查、必要的組織病理學檢查以及次世代定序，以區分PFIC亞型和相關的膽汁淤積症候群。

治療方案包括支持性治療，例如最佳化營養管理和補充維生素；止癢治療；靶向膽汁酸的藥物治療；對合格的患者進行膽道旁路手術；以及對晚期疾病或難治性症狀患者進行肝移植。近年來，治療進展主要得益於髂骨膽汁酸轉運蛋白的抑制、對基因型與表現型之間關係的更深入理解，以及肝病學、遺傳學、小兒科、移植醫學和患者報告結局（PRO）之間更緊密的合作。隨著新生兒和嬰兒基因檢測在許多醫療保健系統中變得更加普及，早期診斷能夠實現更及時的干預、看護者進行教育以及對疾病併發症的監測。

PFIC治療環境的變革性變化

進行性家族性肝內膽汁淤積症 (PFIC) 的治療格局正在經歷一場變革，從以往僅在臨床進展後才確診的階段，轉向早期分子診斷和基於亞型的治療。傳統上，許多患者在經歷漫長的診斷過程後才接受治療，這些過程涉及特異性膽汁淤積症狀、反覆搔癢和進行性肝損傷。如今，基因檢測的廣泛應用提高了對不同類型 PFIC 和表現型疾病（例如阿拉齊爾症候群、膽汁酸合成障礙和其他遺傳性膽汁淤積性疾病）的鑑別診斷能力。這種轉變意義重大，因為治療反應、移植風險、復發風險評估和長期後續觀察可能因基因亞型而異。

人工智慧對PFIC治療的累積影響

人工智慧 (AI) 透過提高罕見疾病識別率、加速文獻整合、輔助基因型解讀以及實現更高效的臨床試驗設計，對整個進行性家族性肝內膽汁淤積症 (PFIC) 治療生態系統產生累積影響。在臨床實踐中，AI 驅動的決策支援系統可以識別兒童持續性膽汁淤積的模式、肝功能檢查異常值、發育不良以及用藥史，這些都可能需要轉診至肝病專家或進行基因檢測。如果使用得當，這些工具可以幫助減少罕見肝病診斷中長期存在的延誤，因為這些疾病的早期症狀可能與更常見的兒童疾病重疊。

PFIC治療市場的關鍵區域洞察

在亞太地區，PFIC治療的可近性受到以下因素的影響：兒童肝病體系的擴展、擁有先進三級醫療網路的國家中基因檢測的日益普及，以及都市區專科醫療中心與農村或資源匱乏地區之間持續存在的差距。在日本、韓國、澳洲、中國和印度，遺傳性肝病的診斷體係正透過基因組醫學計畫和轉診網路得到加強，但在某些地區，費用、保險報銷和認知度低仍然是重要的障礙。在北美，臨床診療日益依賴罕見疾病診斷、兒童肝病專科中心、移植基礎設施和孤兒藥物監管途徑的緊密整合，以及遺傳諮詢、患者權益倡導組織和真實世界數據（REW）的收集。

針對特定族群在啟動 PFIC 治療的關鍵見解。

在東南亞國協，隨著三級醫療網路的擴展和區域醫學培訓的開展，人們對罕見兒童肝病的認知正在逐步提高，但各成員國在PFIC（進行性家族性肝病）的基因檢測、長期藥物治療和移植服務方面仍存在不均衡的現狀。在海灣合作理事會（GCC）成員國中，對基因組醫學、兒童護理和先進醫院基礎設施的投資正在促進遺傳性膽汁淤積性疾病的早期發現。由於體染色體隱性遺傳疾病在近親結婚率較高的人中可能更為常見，因此家庭諮詢尤其重要。在歐盟，透過應對罕見疾病、監管孤兒藥、建立跨境參考網路和協調兒童醫療標準等舉措，已建立起相對系統的PFIC治療體系，但保險報銷和治療獲取所需時間因國家而異。

主要國家PFIC治療趨勢

在美國，透過兒童肝病中心、基因檢測、孤兒藥核准流程、臨床試驗基礎設施和成熟的移植項目，已建立起一套完善的PFIC治療體系，並持續重視患者報告結局和長期安全性證據。加拿大受益於全民健保原則和專業的兒童肝病中心，但地理距離可能會影響居住在主要都會區以外的家庭獲得治療的機會。在墨西哥和巴西，主要轉診醫院的兒童肝病專科水平正在不斷提高，但分子診斷、專科藥物和移植途徑的可及性可能因地區和保險結構而異。英國、德國、法國、義大利和西班牙在應對遺傳性肝病方面擁有強大的能力，這得益於國家醫療體系、專科網路和罕見疾病框架的支持，但醫療技術評估和保險報銷流程的差異會影響患者獲得治療的速度。

針對PFIC治療領域領導者的實用建議

產業領導者應優先考慮以實證醫學為基礎的進行性家族性肝內膽汁淤積症（PFIC）治療策略，以減少診斷延誤、改善症狀管理並支持長期疾病監測。關鍵措施包括加強與兒童肝病中心、基因檢測實驗室、移植計畫和患者登記機構的合作，以累積更可靠的真實世界證據。各機構應投資於小兒科和胃腸病學家的培訓，鼓勵他們在觀察到持續性膽汁淤積、頑固性瘙癢、大便顏色變淺、黃疸和生長遲緩等症狀時儘早轉診並進行基因評估。

了解PFIC治療的調查方法

本執行摘要採用結構化的二級研究方法編寫，重點關注與進行性遺傳性肝內膽汁淤積症 (PFIC) 治療相關的檢驗的臨床、監管、流行病學和醫療保健系統資訊來源。該研究途徑調查方法強調同行評審的肝病學文獻、臨床實踐指南、罕見疾病治療監管文件、公開的兒童肝病登記數據、遺傳醫學資源、移植護理標準以及經認可的公共衛生資訊。證據的評估標準包括臨床相關性、時效性、資訊來源一致性以及對 PFIC 的診斷、治療路徑、區域可近性和新興技術應用的適用性。

結論：在進行性家族性肝內膽汁淤積症（PFIC）的治療中推廣精準醫療。

在基因診斷、膽汁酸代謝途徑創新、多學科兒童診療以及對罕見膽汁淤積性肝病認知不斷提高的推動下，進行性遺傳性肝內膽汁淤積症 (PFIC) 的治療正朝著更加精準、以患者為中心的方向發展。最重要的臨床重點仍然是早期發現、準確的亞型分類、有效控制搔癢、預防營養併發症、監測肝病進展以及根據需要及時轉診以評估手術介入或肝臟移植。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：進行性遺傳性肝內膽汁淤積症的治療市場：依治療類型分類

  • 藥物治療
    • 抗生素
    • 膽汁酸吸附劑
      • 考來烯胺
      • 核心
    • IBAT抑制劑
      • 馬拉利希巴特
      • 奧德比·西巴特
    • 利福平
    • 熊去氧膽酸
  • 支持性護理
    • 營養支持
    • 症狀管理
  • 手術介入
    • 膽道繞道手術
    • 肝臟移植

第8章：進行性遺傳性肝內膽汁淤積症的治療市場：依給藥途徑分類

  • 靜脈
  • 口服

第9章：進行性遺傳性肝內膽汁淤積症的治療市場：依患者年齡層分類

  • 兒童
  • 成人

第10章：進行性遺傳性肝內膽汁淤積症的治療市場：依PFIC類型分類

  • 一型
  • II 型
  • III型

第11章：進行性遺傳性肝內膽汁淤積症的進行性：依最終用戶分類

  • 居家照護
  • 醫院
  • 專科診所

第12章：進行性遺傳性肝內膽汁淤積進行性：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：進行性遺傳性肝內膽汁淤積症的進行性：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：進行性遺傳性肝內膽汁淤積症的進行性：按組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：進行性遺傳性肝內膽汁淤積進行性：依國家分類

  • 美國
  • 中國
  • 德國
  • 英國
  • 日本
  • 印度
  • 加拿大
  • 澳洲
  • 法國
  • 墨西哥
  • 巴西
  • 俄羅斯
  • 義大利
  • 西班牙
  • 韓國

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Axplora Group GmbH
  • CANbridge Pharmaceuticals, Inc.
  • Cipla Limited
  • Glenmark Pharmaceuticals Inc.
  • Healing Pharma India Pvt. Ltd.
  • ICE Pharma
  • Ipsen SA
  • JM Laboratories
  • Lucius Pharmaceuticals
  • Medison Pharma Canada Inc.
  • Mirum Pharmaceuticals, Inc.
  • Nikvin Healthcare
  • Par Health, Inc.
  • Pfizer Inc.
  • Sihauli Chemicals Private Limited
  • Syngene International Limited
  • Takeda Pharmaceutical Company Limited
  • Viatris Inc.
Product Code: MRR-AD517FAAA5F2

The Progressive Familial Intrahepatic Cholestasis Treatment Market is projected to grow by USD 172.81 million at a CAGR of 4.80% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 124.40 million
Estimated Year [2026] USD 129.87 million
Forecast Year [2032] USD 172.81 million
CAGR (%) 4.80%

Progressive familial intrahepatic cholestasis treatment is advancing as rare pediatric liver disease care shifts from symptom management toward precision diagnosis, targeted bile acid modulation, genetic characterization, and transplant-sparing strategies. Progressive familial intrahepatic cholestasis, commonly referred to as PFIC, represents a group of inherited cholestatic disorders caused by defects in hepatocellular bile formation and transport, with clinical features that can include persistent cholestasis, severe pruritus, jaundice, growth impairment, fat-soluble vitamin deficiency, portal hypertension, and progression to liver failure. Diagnosis increasingly relies on biochemical assessment, liver imaging, histopathology when needed, and next-generation sequencing to differentiate PFIC subtypes and related cholestatic syndromes.

The treatment landscape includes supportive care with nutritional optimization and vitamin supplementation, antipruritic therapy, bile acid-directed pharmacology, surgical bile diversion in selected patients, and liver transplantation for advanced disease or refractory symptoms. Recent therapeutic progress has been shaped by ileal bile acid transporter inhibition, improved understanding of genotype-phenotype relationships, and stronger integration of hepatology, genetics, pediatrics, transplant medicine, and patient-reported outcomes. As newborn and early-childhood genetic evaluation becomes more accessible in many health systems, earlier diagnosis is enabling more timely intervention, caregiver education, and monitoring for disease complications.

Transformative Shifts in the PFIC Treatment Landscape

The PFIC treatment landscape is undergoing a transformative shift from late-stage clinical recognition toward earlier molecular diagnosis and subtype-specific management. Historically, many patients were treated after prolonged diagnostic journeys involving nonspecific cholestasis symptoms, recurrent pruritus, and progressive liver injury. Today, broader use of genetic testing is improving differentiation among PFIC types and phenotypically overlapping conditions such as Alagille syndrome, bile acid synthesis defects, and other inherited cholestatic disorders. This change is important because therapeutic response, transplant risk, recurrence considerations, and long-term surveillance can vary by genetic subtype.

Another major shift is the expanding role of non-systemic bile acid pathway therapies designed to reduce enterohepatic bile acid circulation and alleviate cholestatic pruritus. Ileal bile acid transporter inhibitors have changed clinical expectations by offering pharmacologic options for patients who previously relied heavily on off-label antipruritic drugs, invasive diversion procedures, or transplantation when pruritus and disease burden became unmanageable. In parallel, multidisciplinary care models are becoming more structured, combining pediatric hepatology, nutrition, genetic counseling, dermatology, psychosocial support, and transplant evaluation. Regulatory emphasis on rare disease endpoints, caregiver-reported pruritus measures, and long-term safety monitoring is also reshaping evidence generation across PFIC treatment programs.

Cumulative Impact of Artificial Intelligence on PFIC Treatment

Artificial intelligence is exerting a cumulative impact across the PFIC treatment ecosystem by improving rare disease recognition, accelerating literature synthesis, supporting genotype interpretation, and enabling more efficient clinical trial design. In clinical settings, AI-assisted decision support has potential to flag persistent pediatric cholestasis patterns, abnormal liver biochemistry, growth faltering, and medication histories that warrant referral to specialist hepatology or genetic testing. When applied responsibly, these tools can help reduce diagnostic delay, a persistent challenge in rare liver diseases where early symptoms can overlap with more common pediatric conditions.

AI is also strengthening genomic analysis by helping prioritize variants, map genotype-phenotype associations, and support interpretation of large sequencing datasets. In drug development and clinical research, machine learning can support patient identification from registries, optimize inclusion criteria, analyze patient-reported pruritus data, and detect safety patterns across longitudinal datasets. Natural language processing can assist in extracting real-world evidence from clinical notes, registries, and published case series, although outputs require expert validation due to small patient populations and heterogeneous documentation. The cumulative value of AI in PFIC treatment will depend on data quality, interoperability, privacy safeguards, pediatric ethics, transparent algorithms, and integration with specialist clinical judgment rather than replacement of expert care.

Key Regional Insights Across PFIC Treatment Markets

In Asia-Pacific, PFIC treatment access is being shaped by expanding pediatric hepatology capacity, rising use of genetic testing in countries with advanced tertiary care networks, and persistent disparities between urban specialist centers and rural or lower-resource settings. Japan, South Korea, Australia, China, and India are strengthening inherited liver disease diagnosis through genomic medicine initiatives and referral networks, while affordability, reimbursement, and awareness remain important barriers in several areas. North America shows strong integration of rare disease diagnostics, specialist pediatric liver centers, transplant infrastructure, and regulatory pathways for orphan therapies, with clinical care increasingly supported by genetic counseling, patient advocacy, and real-world evidence collection.

Latin America is advancing through tertiary hepatology centers in major economies, but uneven access to genetic sequencing, specialized pediatric hepatologists, and timely transplant referral continues to affect continuity of care. Europe benefits from cross-border rare disease collaboration, pediatric liver networks, and regulatory frameworks that support orphan medicinal products, although country-level reimbursement decisions can influence treatment availability. The Middle East is characterized by growing investment in specialty hospitals and genomic programs, with consanguinity patterns in some populations increasing the importance of inherited disease screening and family counseling. Across Africa, PFIC diagnosis and treatment remain constrained by limited access to molecular diagnostics, pediatric hepatology services, and transplant infrastructure, making capacity building, clinician education, and international referral partnerships critical for improving outcomes.

Key Group Insights Across PFIC Treatment Adoption

ASEAN countries are progressively improving rare pediatric liver disease recognition through expanding tertiary hospital networks and regional medical training, yet access to PFIC genetic testing, long-term pharmacotherapy, and transplant services remains uneven across member states. Within the GCC, investment in genomic medicine, specialized pediatric care, and advanced hospital infrastructure supports earlier identification of inherited cholestatic disorders, while family-based counseling is especially relevant because autosomal recessive diseases can be more visible in populations with higher consanguinity rates. The European Union provides a comparatively structured environment for PFIC treatment through rare disease policies, orphan drug regulation, cross-border reference networks, and efforts to harmonize pediatric care standards, although reimbursement and access timelines differ by country.

BRICS countries represent a diverse PFIC treatment environment, combining large pediatric populations, expanding genetic testing capabilities, and growing specialist centers with substantial differences in affordability, reimbursement, and rural access. G7 countries generally have mature pediatric hepatology systems, transplant capabilities, pharmacovigilance frameworks, and regulatory mechanisms for rare disease therapies, supporting more consistent adoption of evidence-based PFIC care. NATO member states overlap significantly with high-income healthcare systems in North America and Europe, where rare disease preparedness, advanced diagnostics, and collaborative clinical research infrastructure can support improved PFIC detection and management; however, policy alignment does not eliminate national differences in drug access, reimbursement, and specialist availability.

Key Country Insights in PFIC Treatment

The United States demonstrates advanced PFIC treatment capacity through pediatric liver centers, genetic testing access, orphan drug pathways, clinical trial infrastructure, and established transplant programs, with continuing emphasis on patient-reported outcomes and long-term safety evidence. Canada benefits from universal healthcare principles and specialized pediatric hepatology centers, though geographic distance can affect access for families outside major metropolitan areas. Mexico and Brazil have growing expertise in pediatric liver disease within major referral hospitals, but access to molecular diagnostics, specialized medications, and transplant pathways can vary by region and payer structure. The United Kingdom, Germany, France, Italy, and Spain have strong inherited liver disease capabilities supported by national health systems, specialist networks, and rare disease frameworks, while differences in health technology assessment and reimbursement processes influence the pace of therapy access.

Russia has specialist hepatology and genetic medicine capacity concentrated in major urban centers, with regional variability influencing diagnostic timelines and treatment continuity. China is expanding genomic medicine, pediatric specialty hospitals, and liver disease research capacity, supporting broader recognition of inherited cholestasis, although access differences remain between leading urban centers and less-resourced regions. India has increasing availability of genetic testing and pediatric gastroenterology expertise in metropolitan hospitals, while affordability and referral delays remain key practical challenges. Japan and South Korea offer advanced diagnostics, high-quality pediatric specialty care, and structured regulatory environments, supporting precise PFIC diagnosis and monitoring. Australia combines specialist pediatric hepatology services with genomic medicine initiatives, but geographic dispersion can complicate access for remote communities. Across these countries, the most consistent treatment drivers are early genetic diagnosis, specialist referral pathways, nutritional management, pruritus control, and timely consideration of surgical or transplant options when medically necessary.

Actionable Recommendations for PFIC Treatment Leaders

Industry leaders should prioritize evidence-based PFIC treatment strategies that reduce diagnostic delay, improve symptom control, and support long-term disease monitoring. Key actions include strengthening partnerships with pediatric hepatology centers, genetic testing laboratories, transplant programs, and patient registries to build more robust real-world evidence. Organizations should invest in education for pediatricians and gastroenterologists so persistent cholestasis, refractory pruritus, pale stools, jaundice, and growth failure trigger early referral and genetic evaluation.

Therapy developers and care providers should design patient-centered programs that capture pruritus severity, sleep disruption, growth, liver biochemistry, quality of life, caregiver burden, and long-term safety. Access strategies should account for regional differences in reimbursement, genetic testing availability, and specialist distribution. Digital tools can support adherence monitoring, remote symptom tracking, and family education, but they should be validated for pediatric use and integrated into clinician-led care. Leaders should also support equitable access initiatives, including diagnostic assistance, clinician training in lower-resource regions, and ethical data-sharing models that protect children and families while advancing rare disease knowledge.

Research Methodology for PFIC Treatment Insights

This executive summary is developed using a structured secondary research approach focused on verified clinical, regulatory, epidemiological, and health system sources relevant to progressive familial intrahepatic cholestasis treatment. The methodology emphasizes peer-reviewed hepatology literature, clinical practice guidance, regulatory documents on rare disease therapies, pediatric liver disease registries where publicly available, genetic medicine resources, transplant care standards, and recognized public health information. Evidence is assessed for clinical relevance, recency, consistency across sources, and applicability to PFIC diagnosis, treatment pathways, regional access, and emerging technology adoption.

The research approach avoids market sizing, share estimation, and forecasting, focusing instead on qualitative intelligence, treatment dynamics, access determinants, regional readiness, and practical decision factors. Insights are synthesized through disease pathway analysis, stakeholder mapping, therapy landscape review, and regional healthcare capability assessment. Particular attention is given to diagnostic workflows, genetic testing availability, pruritus management, nutritional care, surgical intervention, liver transplantation, patient-reported outcomes, and long-term safety monitoring. Findings are validated through triangulation across multiple credible source categories to reduce reliance on isolated studies or anecdotal evidence.

Conclusion: Advancing Precision Care in PFIC Treatment

Progressive familial intrahepatic cholestasis treatment is entering a more precise and patient-centered era, driven by genetic diagnosis, bile acid pathway innovation, multidisciplinary pediatric care, and improved recognition of rare cholestatic liver disease. The most important clinical priorities remain early identification, accurate subtype classification, effective pruritus control, prevention of nutritional complications, monitoring of liver disease progression, and timely referral for surgical or transplant evaluation when needed.

Regional and country-level differences in genetic testing, specialist availability, reimbursement, and transplant infrastructure continue to shape patient access. Artificial intelligence, real-world evidence, and interoperable registries can strengthen care delivery and research, provided they are implemented with rigorous validation and ethical safeguards. Industry leaders that align therapeutic innovation with diagnostic access, family support, clinician education, and long-term outcome tracking will be best positioned to improve the PFIC treatment journey and support more consistent standards of care across diverse healthcare systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Pharmacotherapy
    • 7.2.1. Antibiotics
    • 7.2.2. Bile Acid Sequestrants
      • 7.2.2.1. Cholestyramine
      • 7.2.2.2. Colesevelam
    • 7.2.3. IBAT Inhibitors
      • 7.2.3.1. Maralixibat
      • 7.2.3.2. Odevixibat
    • 7.2.4. Rifampicin
    • 7.2.5. Ursodeoxycholic Acid
  • 7.3. Supportive Care
    • 7.3.1. Nutritional Support
    • 7.3.2. Symptom Management
  • 7.4. Surgical Interventions
    • 7.4.1. Biliary Diversion
    • 7.4.2. Liver Transplantation

8. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Route Of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral

9. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Patient Age Group

  • 9.1. Introduction
  • 9.2. Pediatrics
  • 9.3. Adults

10. Progressive Familial Intrahepatic Cholestasis Treatment Market, by PFIC Type

  • 10.1. Introduction
  • 10.2. Type I
  • 10.3. Type II
  • 10.4. Type III

11. Progressive Familial Intrahepatic Cholestasis Treatment Market, by End User

  • 11.1. Introduction
  • 11.2. Homecare
  • 11.3. Hospitals
  • 11.4. Specialty Clinics

12. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Hospital Pharmacy
  • 12.3. Online Pharmacy
  • 12.4. Retail Pharmacy

13. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Country

  • 15.1. United States
  • 15.2. China
  • 15.3. Germany
  • 15.4. United Kingdom
  • 15.5. Japan
  • 15.6. India
  • 15.7. Canada
  • 15.8. Australia
  • 15.9. France
  • 15.10. Mexico
  • 15.11. Brazil
  • 15.12. Russia
  • 15.13. Italy
  • 15.14. Spain
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Axplora Group GmbH
  • 17.2. CANbridge Pharmaceuticals, Inc.
  • 17.3. Cipla Limited
  • 17.4. Glenmark Pharmaceuticals Inc.
  • 17.5. Healing Pharma India Pvt. Ltd.
  • 17.6. ICE Pharma
  • 17.7. Ipsen S.A.
  • 17.8. JM Laboratories
  • 17.9. Lucius Pharmaceuticals
  • 17.10. Medison Pharma Canada Inc.
  • 17.11. Mirum Pharmaceuticals, Inc.
  • 17.12. Nikvin Healthcare
  • 17.13. Par Health, Inc.
  • 17.14. Pfizer Inc.
  • 17.15. Sihauli Chemicals Private Limited
  • 17.16. Syngene International Limited
  • 17.17. Takeda Pharmaceutical Company Limited
  • 17.18. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PHARMACOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BILE ACID SEQUESTRANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BILE ACID SEQUESTRANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BILE ACID SEQUESTRANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHOLESTYRAMINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CHOLESTYRAMINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHOLESTYRAMINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COLESEVELAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COLESEVELAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COLESEVELAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IBAT INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IBAT INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IBAT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MARALIXIBAT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MARALIXIBAT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MARALIXIBAT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ODEVIXIBAT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ODEVIXIBAT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ODEVIXIBAT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RIFAMPICIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RIFAMPICIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RIFAMPICIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL URSODEOXYCHOLIC ACID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL URSODEOXYCHOLIC ACID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL URSODEOXYCHOLIC ACID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SUPPORTIVE CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SUPPORTIVE CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SUPPORTIVE CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUTRITIONAL SUPPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NUTRITIONAL SUPPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUTRITIONAL SUPPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SYMPTOM MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SYMPTOM MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SYMPTOM MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SURGICAL INTERVENTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SURGICAL INTERVENTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SURGICAL INTERVENTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BILIARY DIVERSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BILIARY DIVERSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BILIARY DIVERSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LIVER TRANSPLANTATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LIVER TRANSPLANTATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LIVER TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PEDIATRICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PEDIATRICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PEDIATRICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TYPE I MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TYPE I MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TYPE I MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TYPE II MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TYPE II MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TYPE II MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TYPE III MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TYPE III MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TYPE III MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HOMECARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HOMECARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HOMECARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. GCC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GCC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. GCC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 186. GCC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 187. GCC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 188. GCC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 189. GCC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. GCC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GCC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. GCC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. GCC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. G7 PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. G7 PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. G7 PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. G7 PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 222. G7 PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 223. G7 PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 224. G7 PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 225. G7 PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. G7 PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 227. G7 PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. G7 PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. G7 PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. NATO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. NATO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. NATO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 233. NATO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 234. NATO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 235. NATO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 236. NATO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 237. NATO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. NATO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 239. NATO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. NATO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. NATO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 270. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
  • TABLE 271. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY IBAT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 272. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 273. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2032 (USD MILLION)
  • TABLE 274. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 275. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 276. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PFIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED KINGDOM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED KINGDOM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED KINGDOM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED KINGDOM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)

TA